{"a":[{"_":"Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug","$":{"href":"/biotech/jupiter-neurosciences-enter-psychedelic-space-100-million-mdma-deal","hreflang":"en"}}]}

Summary

Jupiter Neurosciences acquired U.S. rights to PharmAla Biotech's MDMA drug for neuropsychiatric disorders for $3.3 million upfront as part of a $100M deal, marking the company's entry into the psychedelics space.